LaborDr.Merk - Boehringer Ingelheim Therapeutics in Ochsenhausen, Germany
Labor Dr.Merk, Lab Dr.Merk, Laboratory Dr.Merk, Laboratory Ochsenhausen, Laboratory Germany, contract research organization Germany, contract development and manufacturing organization Germany, CRO Germany, CRO Ochsenhausen, CDMO Germany, pharmaceutical industry, pharmaceutical industry ochsenhausen, pharmaceutical industry germany, medical device manufactures, contract manufactuig, biosafety testing, vaccine retesting, european market, testing of efficacy of disinfectans, bioassay development, R&D, GMP approved facilities labor germay, expert teams labor germany, lab europe, CRO europe, CMO europe
5
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-5,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,footer_responsive_adv,qode-child-theme-ver-1.0.0,qode-theme-ver-13.6,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-6.8.0,vc_responsive
Welcome at Boehringer Ingelheim Therapeutics GmbH
Boehringer Ingelheim Therapeutics formerly known as Labor Dr. Merk & Kollegen has gathered as a CRO and CDMO comprehensive know-how and capabilities in contract manufacturing, biosafety testing, vaccine retesting for the European market, testing of efficacy of disinfectants, bioassay development and R&D projects with more than40 years of experience and GMP approved facilities.
Following the acquisition, Boehringer Ingelheim Therapeutics will fully focus on supporting the development of Boehringer Ingelheim’s ATMP-based immuno-oncology therapies and the fulfillment of existing external projects.
Boehringer Ingelheim Therapeutics provides a wide range of testing services in the fields of virology, microbiology, immunology and toxicology.
Read more
As a full CDMO with end-to-end process development, manufacturing with analytical characterization and regulatory support, Boehringer Ingelheim Therapeutics provides its partners and its holding company with process GMP manufacturing of viral gene therapeutics, oncolytic viral therapeutics and vaccines.
Read more
Boehringer Ingelheim Therapeutics provides a wide range of testing services in the fields of virology, microbiology, immunology and toxicology.
Read more
As a full CDMO with end-to-end process development, manufacturing with analytical characterization and regulatory support, Boehringer Ingelheim Therapeutics provides its partners and its holding company with process GMP manufacturing of viral gene therapeutics, oncolytic viral therapeutics and vaccines.
Read more
With more than 40 years of relevant experience as a CRO and CDMO, Boehringer Ingelheim Therapeutics supports its partners and holding company in R&D projects.
Read more
Since 1971, Boehringer Ingelheim Therapeutics GmbH has evolved into a diversified testing laboratory and CDMO providing its partners and holding company with process development and GMP manufacturing of viral gene therapeutics, oncolytic viral therapeutics and vaccines, as well as testing services in virology, microbiology, immunology. As of march 2021, Boehringer Ingelheim Therapeutics (Labor Dr. Merk and Kollegen GmbH at that time) became a part of the Boehringer Ingelheim family which performs R&D and clinical manufacturing with a focus on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments.
Read more
With more than 40 years of relevant experience as a CRO and CDMO, Boehringer Ingelheim Therapeutics supports its partners and holding company in R&D projects.
Read more
Since 1971, Boehringer Ingelheim Therapeutics GmbH has evolved into a diversified testing laboratory and CDMO providing its partners and holding company with process development and GMP manufacturing of viral gene therapeutics, oncolytic viral therapeutics and vaccines, as well as testing services in virology, microbiology, immunology. As of march 2021, Boehringer Ingelheim Therapeutics (Labor Dr. Merk and Kollegen GmbH at that time) became a part of the Boehringer Ingelheim family which performs R&D and clinical manufacturing with a focus on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments.
Read more
Do you enjoy working in small project teams with flat hierarchies? We are always looking for motivated people to join our team!
Read more
Do you have a question? Then please don’t hesitate to contact us via phone, email or using the form below. We will be in touch as soon as possible!
Read more
Do you enjoy working in small project teams with flat hierarchies? We are always looking for motivated people to join our team!
Read more
Do you have a question? Then please don’t hesitate to contact us via phone, email or using the form below. We will be in touch as soon as possible!
Read more
Pressemitteilung englisch
Boehringer Ingelheim and Labor Dr. Merk & Kollegen today announced the transaction closing for the acquisition of Labor Dr. Merk & Kollegen by Boehringer Ingelheim. Following the signing of the agreement for the acquisition in December 2020, the approval of the competition authorities in Germany as well as further formalities for the conclusion of the deal have now been completed.
With Labor Dr. Merk & Kollegen, Boehringer Ingelheim establishes a fully integrated expertise hub for the development and clinical manufacturing of therapeutic viruses.
In August 2019 LMK successfully passed an inspection by the competent authority Regierungspräsidium Tübingen which ended now in the permission to manufacture an oncolytic virus with immune-stimulatory cargo. So LMK holds now a Manufacturing Authorization for a Drug Substance in the context of ATMPs („Advanced Therapy Medicinal Products“) according to the German Drug Law § 15 Abs. 3a S.1 Nr.6.
In September 2018 LMK successfully passed an extensive inspection by the FDA. We owe this success to our highly competent and professional staff. The authority’s expectations were met in full, after assessing LMK’s laboratory facilities and quality assurance system against strict cGMP standards. In the closing meeting the FDA inspector emphasized his appreciation for LMK’s comprehensive and coherent data as well as for our well established procedures to secure data integrity.
Boehringer Ingelheim and Labor Dr. Merk & Kollegen today announced the transaction closing for the acquisition of Labor Dr. Merk & Kollegen by Boehringer Ingelheim. Following the signing of the agreement for the acquisition in December 2020, the approval of the competition authorities in Germany as well as further formalities for the conclusion of the deal have now been completed.
With Labor Dr. Merk & Kollegen, Boehringer Ingelheim establishes a fully integrated expertise hub for the development and clinical manufacturing of therapeutic viruses.
Manufacturing Authorization
In August 2019 LMK successfully passed an inspection by the competent authority Regierungspräsidium Tübingen which ended now in the permission to manufacture an oncolytic virus with immune-stimulatory cargo. So LMK holds now a Manufacturing Authorization for a Drug Substance in the context of ATMPs („Advanced Therapy Medicinal Products“) according to the German Drug Law § 15 Abs. 3a S.1 Nr.6.
In September 2018 LMK successfully passed an extensive inspection by the FDA. We owe this success to our highly competent and professional staff. The authority’s expectations were met in full, after assessing LMK’s laboratory facilities and quality assurance system against strict cGMP standards. In the closing meeting the FDA inspector emphasized his appreciation for LMK’s comprehensive and coherent data as well as for our well established procedures to secure data integrity.
